On the Imbalance of Distributions of Solutions of CNF-Formulas and its Impact on Satisfiability Solvers

Let F be Boolean formulas in conjunctive normal form with n variables, r clauses, every clause has length s. We show that if F is split into two subformulas F_{v} and F_{overline{v}} by setting v true and false in F, then the expected number of solutions of one of the two subformulas F_{v} and F_{overline{v}} is significantly higher than that in the other subformula, when dealing with classes of formulas where the great majority of formulas is satisfiable. We discuss practical consequences of this result

Improving a fixed parameter tractability time bound for the shadow problem

AbstractConsider a forest of k trees and n nodes together with a (partial) function σ mapping leaves of the trees to non-root nodes of other trees. Define the shadow of a leaf ℓ to be the subtree rooted at σ(ℓ). The shadow problem asks whether there is a set S of leaves exactly one from each tree such that none of these leaves lies in the shadow of another leaf in S. This graph theoretical problem as shown in Franco et al. (Discrete Appl. Math. 96 (1999) 89) is equivalent to the falsifiability problem for pure implicational Boolean formulas over n variables with k occurences of the constant false as introduced in: Heusch J. Wiedermann, P. Hajek (Eds.), Proceedings of the Twentieth International Symposium on Mathematical Foundations of Computer Science (MFCS’95), Prague, Czech Republic, Lecture Notes in Computer Science, Vol. 969, Springer, Berlin, 1995, pp. 221–226, where its NP-completeness is shown for arbitrary values of k and a time bound of O(nk) for fixed k was obtained. In Franco et al. (1999) this bound is improved to O(n2kk) showing the problem's fixed parameter tractability (Congr. Numer. 87 (1992) 161). In this paper the bound O(n33k) is achieved by dynamic programming techniques thus significantly improving the fixed parameter part

CATS - Computer Aided Tram Scheduling

If public transport systems circulate periodically (e.g. 4 times per hour), their timetable is completely determined by the timetable for a single period, the so-called initial timetable. The initial timetable can then be used to calculate the other schedules, mainly those for vehicles and those for crews. In our project CATS we deal with the computer aided construction and optimization of initial timetables. We currently develop a tool that allows for a simple user interface, very similar to the normally used paper-based user interface, which eases the task of construction while at the same time the developed plan is checked against the set of constraints. The data is stored in a database to facilitate the communication between timetable construction and the following steps

Dark consequences from light neutrino condensations

In this paper we discuss light neutrino dipole moments, computed in the neutrino-mass extended standard model (SM), as a possible source for neutrino condensates which may cause cosmological constant observed today.Comment: 5 pages; version to appear in PL

On the quest for unification - simplicity and antisimplicity

The road towards unification of elementary interactions is thought to start on the solid ground of a universal local gauge principle. I discuss the different types of bosonic gauge symmetries in gravitational and nongravitational (standard model) interactions and their extensions both fermionic, bosonic and with respect to space-time dimensions. The apparently paradoxical size and nature of the cosmological constant is sketched, which at first sight does not readily yield a clue as to the envelopping symmetry structure of a unified theory. Nevertheless a tentative outlook is given encouraging to proceed on this road.Comment: 29 pages, 4 figure

Translating cardioprotection for patient benefit: Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients

From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research"

In this meeting report, particularly addressing the topic of protection of the cardiovascular system from ischemia/reperfusion injury, highlights are presented that relate to conditioning strategies of the heart with respect to molecular mechanisms and outcome in patients' cohorts, the influence of co-morbidities and medications, as well as the contribution of innate immune reactions in cardioprotection. Moreover, developmental or systems biology approaches bear great potential in systematically uncovering unexpected components involved in ischemia-reperfusion injury or heart regeneration. Based on the characterization of particular platelet integrins, mitochondrial redox-linked proteins, or lipid-diol compounds in cardiovascular diseases, their targeting by newly developed theranostics and technologies opens new avenues for diagnosis and therapy of myocardial infarction to improve the patients' outcome

Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection

The present review summarizes the beneficial and detrimental roles of reactive oxygen species in myocardial ischemia/reperfusion injury and cardioprotection. In the first part, the continued need for cardioprotection beyond that by rapid reperfusion of acute myocardial infarction is emphasized. Then, pathomechanisms of myocardial ischemia/reperfusion to the myocardium and the coronary circulation and the different modes of cell death in myocardial infarction are characterized. Different mechanical and pharmacological interventions to protect the ischemic/reperfused myocardium in elective percutaneous coronary interventions and coronary artery bypass grafting, in acute myocardial infarction and in cardiotoxicity from cancer therapy are detailed. The second part keeps the focus on ROS providing a comprehensive overview of molecular and cellular mechanisms involved in ischemia/reperfusion injury. Starting from mitochondria as the main sources and targets of ROS in ischemic/reperfused myocardium, a complex network of cellular and extracellular processes is discussed, including relationships with Ca2+ homeostasis, thiol group redox balance, hydrogen sulfide modulation, cross-talk with NAPDH oxidases, exosomes, cytokines and growth factors. While mechanistic insights are needed to improve our current therapeutic approaches, advancements in knowledge of ROS-mediated processes indicate that detrimental facets of oxidative stress are opposed by ROS requirement for physiological and protective reactions. This inevitable contrast is likely to underlie unsuccessful clinical trials and limits the development of novel cardioprotective interventions simply based upon ROS removal

Levosimendan Administration in Limb Ischemia: Multicomponent Signaling Serving Kidney Protection

AIMS AND OBJECTIVES: Acute renal failure is a severe complication of lower extremity major arterial reconstructions, which could even be fatal. Levosimendan is a dual-acting positive inotropic and vasodilatory agent, which is suspected to have protective effects against cardiac ischemia. However, there is no data available on lower limb or remote organ ischemic injuries therefore the aim of the study was to investigate the effect of levosimendan on lower limb ischemia-reperfusion injury and the corollary renal dysfunction. METHODS: Male Wistar rats underwent 180 min bilateral lower limb ischemia followed by 4 or 24 hours of reperfusion. Intravenous Levosimendan was administered continuously (0.2mug/bwkg/min) throughout the whole course of ischemia and the first 3h of reperfusion. Results were compared with sham-operated and ischemia-reperfusion groups. Hemodynamic monitoring was performed by invasive arterial blood pressure measurement. Kidney and lower limb muscle microcirculation was registered by a laser Doppler flowmeter. After 4h and 24h of reperfusion, serum, urine and histological samples were collected. RESULTS: Systemic hemodynamic parameters and microcirculation of kidney and the lower limb significantly improved in the Levosimendan treated group. Muscle viability was significantly preserved 4 and 24 hours after reperfusion. At the same time, renal functional laboratory tests and kidney histology demonstrated significantly less expressive kidney injury in Levosimendan groups. TNF-alpha levels were significantly less elevated in the Levosimendan group 4 hours after reperfusion. CONCLUSION: The results claim a protective role for Levosimendan administration during major vascular surgeries to prevent renal complications